We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Next-Generation Benchtop Diagnostic Platform Delivers Rapid Multi-Gene Test Results

By LabMedica International staff writers
Posted on 27 Nov 2023

In today’s rapidly advancing healthcare sector, the implementation of multi-gene testing is increasingly crucial. More...

This method efficiently uses limited tissue samples and significantly speeds up the time to get critical results. Now, a benchtop diagnostic platform for fully integrated analysis of molecular biomarker signatures with a 4-hour automated workflow allows hospitals and pathology labs to bring this advanced technology in-house, leading to quicker results and enhanced coordination in patient care.

BIOTYPE GmbH (Dresden, Germany) has significantly upgraded its MODAPLEX platform, making it easier for research and clinical labs to conduct sophisticated molecular analyses swiftly and automatically. The MODAPLEX system stands out for its ability to simultaneously detect and assess crucial biomarkers using a simple process. With an efficient workflow that takes less than four hours, the platform provides pathologists and clinicians with rapid and precise results. It enables the simultaneous measurement of key RNA and DNA biomarkers from a single sample, facilitating prompt initiation of optimal therapy and contributing to healthcare system efficiency.

BIOTYPE is now introducing an enhanced version of its hardware platform, featuring simplified software for automated analysis of cancer-related RNA and DNA biomarkers. The open-system nature of the MODAPLEX platform allows third parties, including molecular testing system developers and pharmaceutical companies, to create and distribute their own assays. This strategy broadens the range of available tests and makes the MODAPLEX platform more appealing to users who prefer sourcing test kits from various providers.

"The launch of the next-generation MODAPLEX system also marks our entry into the international business for molecular testing platforms," said Dr Norman Gerstner, CEO of BIOTYPE GmbH. "Last year, we repositioned the company in the rapidly growing precision medicine market. In addition to molecular tests for highly specialized diagnostics of complex diseases, we are now expanding our portfolio to include software and instruments. In addition, MODAPLEX is making an important contribution to meeting the growing demand for sophisticated technologies for multi-gene testing. MODAPLEX maximizes the use of existing tissue samples and reduces critical turnaround times."

Related Links:
BIOTYPE GmbH


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Myocardial Infarction Test
Finecare cTn I/NT-proBNP Rapid Quantitative Test
New
C-Reactive Protein Rapid Test
Afinion CRP
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Switching to an experimental drug after liquid biopsy detection of breast cancer recurrence can improve outcomes (Photo courtesy of Shutterstock)

Treatment Switching Guided by Liquid Biopsy Blood Tests Improves Outcomes for Breast Cancer Patients

Standard treatment for patients with advanced estrogen receptor (ER)-positive, HER2-negative breast cancer, a subtype driven by estrogen receptors that fuel tumor growth, often involves aromatase inhibitors,... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.